Is Eurofins Scientific (ENXTPA:ERF) Attractively Priced After Recent Share Price Weakness?

Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.

• Wondering if Eurofins Scientific at €59.34 is offering good value right now, or if the recent price leaves limited upside? This article breaks down what the current market price might be implying.

• The stock is up 0.5% over the last week, while the 30 day return is a 9.1% decline and the year to date return is a 4.3% decline. This is set against a 6.6% gain over the past year and 4.1% over three years, but a 22.8% decline over five years.

• Recent coverage has focused on Eurofins Scientific as a key player in life sciences testing and diagnostics. This includes commentary on how the business model fits into long term demand for laboratory services, adding context for investors watching how sentiment around the stock shifts over time.

• Eurofins Scientific currently has a valuation score of 5/6. The next sections will compare what different valuation methods say about that score and will point to an even more useful way to think about value that will be covered at the end.

Eurofins Scientific delivered 6.6% returns over the last year. See how this stacks up to the rest of the Life Sciences industry.

Approach 1: Eurofins Scientific Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company might be worth by projecting its future cash flows and then discounting those back to today to reflect risk and the time value of money.

For Eurofins Scientific, the model used is a 2 Stage Free Cash Flow to Equity approach built on cash flow projections. The last twelve months Free Cash Flow is €726.5 million. Analyst estimates are available for the next few years and Simply Wall St extrapolates beyond that, with projected Free Cash Flow of €1,486.0 million in 2030 and further annual figures through 2035.

Bringing all those projected cash flows back to today, the DCF model arrives at an estimated intrinsic value of €196.54 per share. Compared with the current share price of €59.34, this implies the stock is 69.8% undervalued according to this method.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Eurofins Scientific is undervalued by 69.8%. Track this in your watchlist or portfolio, or discover 227 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Eurofins Scientific.

Approach 2: Eurofins Scientific Price vs Earnings

For profitable companies, the P/E ratio is a useful way to see how much you are paying for each euro of current earnings. A higher or lower P/E often reflects what the market is pricing in for growth and risk, with faster growth and lower perceived risk usually supporting a higher “normal” or “fair” P/E.

Eurofins Scientific currently trades on a P/E of 25.1x. This stands below the Life Sciences industry average of 36.5x and also below the peer group average of 30.9x, suggesting the stock is priced more conservatively than many comparable companies on this simple metric.

Simply Wall St’s Fair Ratio for Eurofins Scientific is 19.7x. This is a proprietary estimate of what the P/E might be, given factors such as earnings growth, industry, profit margin, market cap and specific risks. Because it is tailored to the company’s own profile, the Fair Ratio can be more informative than a straight comparison with broad industry or peer averages.

With the current P/E of 25.1x sitting above the Fair Ratio of 19.7x, the stock appears expensive relative to this company specific yardstick.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 99 top founder-led companies.

Upgrade Your Decision Making: Choose your Eurofins Scientific Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced here as your way of attaching a clear story about Eurofins Scientific to concrete numbers like fair value, and assumptions for future revenue, earnings and margins, so that the company’s story, the forecast, and the fair value all line up in one place on Simply Wall St’s Community page, which is used by millions of investors, and then update automatically as fresh news or earnings arrive, helping you compare fair value with the current price and decide if Eurofins Scientific at €59.34 looks closer to a higher fair value such as €93.0 or to a lower fair value such as €46.0 based on the narrative you find most convincing.

For Eurofins Scientific however we will make it really easy for you with previews of two leading Eurofins Scientific Narratives:

🐂 Eurofins Scientific Bull Case

Fair value in this bullish narrative: €93.00

Implied undervaluation versus €59.34: 36.2%

Revenue growth assumption: 8.9%

• Views Eurofins Scientific as benefiting from digital and infrastructure investment, with efficiency gains and higher margins already feeding into analyst assumptions.

• Sees growth coming from advanced testing demand and specialty areas such as genomics and advanced diagnostics, with analysts using this to support higher earnings and free cash flow expectations.

• Anchors a €93.00 fair value on assumptions for stronger revenue, higher profit margins and a future P/E that is below where the wider Life Sciences group is currently referenced in the narrative.

🐻 Eurofins Scientific Bear Case

Fair value in this bearish narrative: €48.00

Implied overvaluation versus €59.34: 23.1%

Revenue growth assumption: 4.9%

• Highlights risks from automation, client insourcing and tighter regulation that could weigh on Eurofins Scientific’s traditional lab activities and margins.

• Flags concerns that ongoing expansion and acquisitions may leave the company with underused assets, higher integration costs and weaker pricing power against large clients.

• Uses more cautious assumptions on revenue growth, margins and a lower future P/E to arrive at a €48.00 fair value that sits well below the current share price in this scenario.

Having both narratives side by side lets you decide which set of assumptions feels closer to how you see Eurofins Scientific’s future, and whether the current price around €59.34 fits better with the higher or lower fair value story in your own portfolio context.

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Eurofins Scientific on Simply Wall St. Add the company to your watchlist or portfolio so you’ll be alerted when the story evolves.

Do you think there’s more to the story for Eurofins Scientific? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ERF.PA.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com